Middle East & Africa Malaria Treatment Market

The Middle East & Africa malaria treatment market was valued at US$ 2,091.28 million in 2022 and is expected to reach US$ 15,512.97 million by 2030; it is estimated to grow at a CAGR of 28.5% from 2022 to 2030. 

Extending Pipeline of New Drugs and Vaccines Fuels Middle East & Africa Malaria Treatment Market

Antimicrobial resistance can put the public at risk of many diseases, such as malaria. To overcome this challenge, the R&D of new medicines is considered the best strategy; as a result, the antimalarial pipeline is becoming increasingly robust. Public-private partnerships are accelerating research activities related to the treatment of malaria. For instance, Medicines for Malaria Venture (MMV), a nonprofit organization, works with numerous pharmaceutical companies to reduce the burden of malaria by developing novel treatment options. Therefore, the growing number of antimalarial and drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

A few antimalarial that are under clinical development are mentioned in the table below:

Table 1.    Malaria Drugs/Vaccine/Compounds Under Clinical Development

Drug    Developer    Clinical Trial Stage

Artefenomel    Sanofi     Phase IIb

KAE609     Novartis AG    Phase IIb

KAF156    Novartis AG    Phase IIb

DSM265    Takeda Pharmaceutical Company    Phase IIa

SANARIA PfSPZ-GA1    Sanaria    Phase II

SANARIA PfSPZ Vaccine - Radiation Attenuated PfSPZ Vaccine    Sanaria    Phase II

SANARIA PfSPZ-CVac    Sanaria    Phase II

MSP3-CRM-Vac4All    Vac4All    Phase I

Liver-Stage Antigen-3 (LSA3)    Vac4All    Phase IIa

Source: Company Website, The Insight Partners Analysis

Therefore, the growing number of antimalarial and drugs/vaccines that are under clinical development are expected to boost the market growth in the future.

Middle East & Africa Malaria Treatment Market Overview

The malaria treatment market in the Rest of Middle East & Africa is segmented into Israel, Iran, Iraq, Kuwait, Oman, Egypt, Quatar, and others. The Mediterranean Journal of Hematology and Infectious Diseases report states that imported malaria poses a serious health problem in Qatar. For example, imported malaria in Qatar increased during the past seven years despite the constant reduction, and the most affected were adult male migrants from endemic countries. Moreover, non-governmental organizations have stepped in to provide health education and preventative tools in countries where malaria is endemic. Furthermore, federal governments have also invested in commercials to educate the public on malaria transmission as well as methods of protection and treatment, which is likely to boost the market for malaria treatment in the Rest of Middle East & Africa.

Middle East & Africa Malaria Treatment Market Revenue and Forecast to 2030 (US$ Million)

Middle East & Africa Malaria Treatment Strategic Insights

Strategic insights for the Middle East & Africa Malaria Treatment provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Middle East & Africa Malaria Treatment Report Scope

Middle East & Africa Malaria Treatment Regional Insights

The geographic scope of the Middle East & Africa Malaria Treatment refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

Middle East & Africa Malaria Treatment Market Segmentation 

The Middle East & Africa malaria treatment market is segmented based on treatment, route of administration, distribution channel, and country. Based on treatment, the Middle East & Africa malaria treatment market is segmented into generic drugs, originators, vaccines, and others. The vaccines segment held the largest market share in 2022. 

In terms of route of administration, the Middle East & Africa malaria treatment market is bifurcated into oral and parenteral. The oral segment held a larger market share in 2022. 

By distribution channel, the Middle East & Africa malaria treatment market is segmented into direct tender, hospital pharmacies, retail pharmacies, online pharmacies, and others. The direct tender segment held the largest market share in 2022. 

Based on country, the Middle East & Africa malaria treatment market is segmented into South Africa, Saudi Arabia, the UAE, Kenya, Tanzania, Rwanda, Nigeria, Ghana, Uganda, Angola, Cameroon, Senegal, Zambia, and the Rest of Middle East & Africa. The Rest of Middle East & Africa dominated the Middle East & Africa malaria treatment market share in 2022. 

Cipla Ltd, Sun Pharmaceutical Industries Ltd, Sanofi SA, GSK Plc, Novartis AG, Pfizer Inc, and Lupin Ltd are some of the leading players operating in the Middle East & Africa malaria treatment market.